Navigation Links
ApoCell's Cancer Predictive Index Helps Oncologists Select the Most,Effective Targeted Drug Therapy

HOUSTON--(BUSINESS WIRE)--Jun 7, 2007 - ApoCell, Inc. presented the results of a study conducted by researchers at the University of Chicago and ApoCell at the 2007 annual meeting of the American Society of Clinical Oncology (ASCO) held in Chicago in early June. The study showed that ApoCell's advanced pharmacodynamic biomarker assay technology provides reliable predictive data of clinical response. This study showed the benefit of treating aggressive head and neck cancer patients with a combination of targeted molecular drugs.

Cancer treatment is evolving from the use of highly toxic systemic compounds to targeted molecular drugs that are safer and faster acting because they aim only at cancer cell structures and their bio-mechanisms. Pharmacodynamics is an evolving field that encompasses the study of the biochemical and physiological effects of drugs, the mechanisms of drug action and the relationship between drug concentration and biological effect.

ApoCell has developed an analytical tool, the PDx Index(TM) (Pharmaco-Diagnostic Index), which indicates the likelihood of whether a targeted therapy will elicit a clinical response. The predictive index in this study was derived by comparing the biochemical state of a cancer cell receptor that is critical to the process of angiogenesis or vascularization of tumors. This PDx Index(TM) of patients with head and neck cancer showed a direct correlation between the drug regimen and patient response. This new technology is applicable to predicting the clinical outcome of most molecular targeted cancer drugs.

Dr. Darren Davis, ApoCell's President and CEO comments, "We have developed the PDx Index(TM) methodology to give drug developers, clinical investigators and oncologists a quantitative tool to predict effectiveness of cancer drug treatment. Recent research has demonstrated that different individuals respond differently to the same cancer drug therapy. By knowing a patient's PDx Index(TM) score ahead of time, the physician can prescribe the right drug treatment that has the highest probability of success for that individual."

About ApoCell, Inc.

ApoCell was founded in 2004 to commercialize biomarker technologies that were developed at the University of Texas M.D. Anderson Cancer Center. This proprietary method monitors the effectiveness of cancer drugs by measuring biomarker expression patterns in patient specimens. ApoCell provides analytical biomarker services to pharmaceutical and biotechnology companies, and clinical researchers in academia and government to assist them in developing new therapeutic agents. ApoCell's technology has been tested in 38 clinical studies with over 11,000 specimens on 28 investigational drugs including six FDA approved cancer drugs. ApoCell's molecular-based diagnostics have application in oncology and other diseases. For more information, please visit www.apocell.com.

Contact

ApoCell, Inc., Houston
Darren Davis, 713-440-6070


'"/>




Related medicine technology :

1. Breast Cancer and HER-2/neu: Diagnostic Tools for Targeted Therapy
2. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
3. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
4. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
5. Protox Announces Positive Clinical Data from Prostate Cancer Study
6. Gene Therapy Eradicates Pancreatic Cancer in Preclinical Trial Targeting Systems Success in Mouse Model Reported in Cancer Cell
7. MediGene Announces Cancer-Fighting Virus Shows Promise in Early Clinical Trial
8. Response Genetics Announces Publication of a Phase III Clinical Trial Demonstrating That Low Levels of ERCC-1 Help to Predict Likelihood of Response to Cisplatin-Based Therapy in Lung Cancer
9. Study Shows Ixabepilone Demonstrated Clear Activity in Patients with Metastatic Breast Cancer Resistant to Anthracycline, Taxane, and Capecitabine
10. Peer Reviewed Journal Article Indicates Repros Proellex Exhibits Potential for New Approach to the Treatment and Prevention of Breast Cancer
11. Rosetta Genomics and Weizmann Institute Scientists Identify Role of microRNA in Cancer Suppression
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2016)... May 4, 2016 ... the  "Global Multiple Myeloma Market and Competitive ... offering.       (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO ... and Competitive Landscape Highlights 2016, provides comprehensive ... Myeloma epidemiology, Multiple Myeloma market valuations and ...
(Date:5/4/2016)... , May 4, 2016 ... of the  "Global Acute Myeloid Leukemia Market ... to their offering.       (Logo: ... Myeloid Leukemia Market and Competitive Landscape Highlights ... Leukemia pipeline products, Acute Myeloid Leukemia epidemiology, ...
(Date:5/4/2016)... 2016 Research and ... Acute lymphocytic Leukemia Market and Competitive Landscape ...      (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO ... Market and Competitive Landscape Highlights 2016, provides ... products, Acute Lymphocytic Leukemia epidemiology, Acute Lymphocytic ...
Breaking Medicine Technology:
(Date:5/5/2016)... ... May 05, 2016 , ... TIME for Kids and The ZAC ... a new partnership to reach nearly 1 million children with important water safety messages ... is the leading cause of accidental death in children one to 6 years of ...
(Date:5/5/2016)... ... 05, 2016 , ... The 2016 Nike Soccer Camp will be directed by ... coaching staff. Together they bring their winning Vandals coaching philosophy to young athletes. Programs ... 5-13, and high school players. Session dates are as follows: , Youth Day Camp ...
(Date:5/5/2016)... ... May 05, 2016 , ... United Collection Bureau, Inc. (UCB) announces ... more than 15 years of experience within the healthcare revenue cycle industry. With a ... the Director of Patient Financial Services at Spectrum Health. While at Spectrum Health, Clark ...
(Date:5/5/2016)... , ... May 05, 2016 , ... ... honored finalists and winners Tuesday evening, May 3, at the 2016 ISE® Central ... , Scott Pettigrew, Vice President and Chief Security Officer of HMS, was selected ...
(Date:5/5/2016)... ... May 05, 2016 , ... ACLS Certification Institute, a ... new referral program, giving participants incentive for spreading the word about the Institute’s ... know many professionals share resources with their friends and colleagues,” said Vonda Andrews, ...
Breaking Medicine News(10 mins):